

Title (en)

CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF

Title (de)

DURCH ZELLOBERFLÄCHENPROTEASEN AKTIVIERTE KONJUGATE UND THERAPEUTISCHE VERWENDUNGEN DAVON

Title (fr)

CONJUGUES ACTIVES PAR DES PROTEASES DE SURFACE CELLULAIRE ET LEURS UTILISATIONS THERAPEUTIQUES

Publication

**EP 1545572 A4 20060412 (EN)**

Application

**EP 02739474 A 20020523**

Priority

- US 0216819 W 20020523
- US 29326701 P 20010523

Abstract (en)

[origin: WO02095007A2] Conjugates, compositions and method for treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases, are provided. The conjugates for use in the compositions and methods are peptidic conjugates that contain therapeutic, including cytotoxic, agents.

IPC 1-7

**A61K 38/00**; **A61K 38/04**; **A61K 38/28**; **A61K 31/70**; **C07K 14/00**; **C07K 16/00**; **C07K 17/00**

IPC 8 full level

**A61K 31/337** (2006.01); **A61K 31/704** (2006.01); **A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61K 45/00** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61P 5/00** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 17/00** (2006.01); **A61P 17/02** (2006.01); **A61P 17/06** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 7/06** (2006.01)

CPC (source: EP KR)

**A61K 47/50** (2017.07 - KR); **A61K 47/642** (2017.07 - EP); **A61P 5/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)

- [PX] WO 0136604 A2 20010525 - CORVAS INT INC [US], et al
- [PX] WO 0168145 A2 20010920 - DU PONT PHARM CO [US]
- [E] WO 03068934 A2 20030821 - RUTTER WILLIAM J [US]
- [E] WO 03104394 A2 20031218 - DENDREON SAN DIEGO LLC [US], et al
- [E] WO 03000201 A2 20030103 - DRUG INNOVATION & DESIGN INC [US], et al
- [XY] MASQUELIER M ET AL: "AMINO ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 1. SYNTHESIS, PHYSICO-CHEMICAL PROPERTIES, AND LYSOSOMAL DIGESTION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 23, no. 11, 1980, pages 1166 - 1170, XP000914522, ISSN: 0022-2623
- [Y] TAKEUCHI T ET AL: "Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 25 AUG 2000, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26333 - 26342, XP002355779, ISSN: 0021-9258
- [XPY] GARSKY V M ET AL: "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.", JOURNAL OF MEDICINAL CHEMISTRY. 22 NOV 2001, vol. 44, no. 24, 22 November 2001 (2001-11-22), pages 4216 - 4224, XP002355780, ISSN: 0022-2623
- See references of WO 02095007A2

Cited by

US10875848B2; US11299484B2; US10793554B2; US11267805B2; US10399951B2; US10450286B2; US10457655B2; US10472342B2; US10800750B2; US10995078B2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**WO 02095007 A2 20021128**; **WO 02095007 A3 20050506**; CA 2447023 A1 20021128; EP 1545572 A2 20050629; EP 1545572 A4 20060412; JP 2005518332 A 20050623; KR 20040004642 A 20040113

DOCDB simple family (application)

**US 0216819 W 20020523**; CA 2447023 A 20020523; EP 02739474 A 20020523; JP 2002592470 A 20020523; KR 20037015240 A 20031121